Sulfonamides and Sulfonylated Derivatives as Anticancer Agents

Authors: casini A.; Scozzafava A.; Mastrolorenzo A.; Supuran C.T.

Source: Current Cancer Drug Targets, Volume 2, Number 1, March 2002 , pp. 55-75(21)

Publisher: Bentham Science Publishers

Abstract:

The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anti-carbonic anhydrase, diuretic, hypoglycemic and antithyroid activity among others. A host of structurally novel sulfonamide derivatives have recently been reported to show substantial antitumor activity in vitro and / or in vivo. Although they have a common chemical motif of aromatic / heterocyclic sulfonamide, there are a variety of mechanisms of their antitumor action, such as carbonic anhydrase inhibition, cell cycle arrest in the G1 phase, disruption of microtubule assembly, functional suppression of the transcriptional activator NF-Y, and angiogenesis (matrix metalloproteinase, MMP) inhibition among others. Some of these compounds selected via elaborate preclinical screenings or obtained based on computer-aided drug design, are currently being evaluated in clinical trials. This review summarizes recent classes of sulfonamides and related sulfonyl derivatives disclosed ultimately as effective tumor cell growth inhibitors, or for the treatment of different types of cancer.

Keywords: Sulfonamides; Sulfonylated Derivatives; Anticancer Agents; anti-carbonic anhydrase; diuretic; hypoglycemic; antithyroid; transcriptional activator NF-Y; angiogenesis; matrix metalloproteinase MMP

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1568009023334060

Publication date: 2002-03-01

• Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
  Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
  As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

• In this: publication
• By this: publisher
• In this Subject: Oncology ,  Pharmacology
• By this author: casini A. ;  Scozzafava A. ;  Mastrolorenzo A. ;  Supuran C.T.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers